Valneva SE
VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.53
Price+10.13%
$1.06
1Y
Price
Market Cap
$909.827m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$186.057m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$80.388m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$1.15
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$175.253m
$482.242m
Assets$306.989m
Liabilities$211.147m
DebtDebt to Assets
43.8%
-3.8x
Debt to EBITDAFree Cash Flow
-$60.319m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company